PTC THERAPEUTICS, INC.
About PTC THERAPEUTICS, INC.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.7B
- Net income
- $682.6M
- Total assets
- $2.9B
- Market cap
- $5.9B
- Operating margin
- 50.1%
- Net margin
- 39.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.7B
- Operating expenses
- $863.7M
- Operating income
- $866.9M
- Income tax
- $14.0M
- Net income
- $682.6M
- EPS (basic)
- $8.58
- EPS (diluted)
- $7.78
Balance sheet
- Total assets
- $2.9B
- Current assets
- $2.3B
- Total liabilities
- $3.1B
- Current liabilities
- $968.4M
- Shareholders’ equity
- -$205.3M
Cash flow
- Operating cash flow
- $711.2M
- Investing cash flow
- -$862.0M
- Financing cash flow
- $331.1M
- Net cash flow
- $180.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $5.9B
- P/E ratio
- 9.1
- EPS (diluted)
- $7.78
- Shares outstanding
- 83.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 20, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $682.6M in FY2025.
- Revenue grew 355% from FY2020 to FY2025.
- Trading 18% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 9.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PTC THERAPEUTICS, INC..
Write a review
News about PTC THERAPEUTICS, INC.
News & sentiment via Polygon.io
